Hubble Therapeutics

This animated communication piece was developed for Hubble Therapeutics, a biotechnology company advancing gene therapy for Leber Congenital Amaurosis Type 16 (LCA16), a rare genetic retinal disease that causes progressive vision loss and blindness.

The animation presents the biological challenges of LCA16 and illustrates how the therapy aims to restore retinal function by delivering healthy gene copies into retinal cells, translating complex gene therapy concepts into clear visual explanations for both scientific and non-specialist audiences.

Project Use & Impact: The animation was used in investor presentations, partnership discussions, and patient advocacy outreach to communicate Hubble's therapeutic approach, helping diverse stakeholders understand the science and potential impact of the treatment.

Key challenge: Making specialized gene therapy research comprehensible and compelling across technical and non-technical stakeholders in the rare disease community.

Studio roles:
Art Direction, Illustration: Neda Ivanova
Animation, storyboard, sound design: Life Science Animation

Diagram of a cell membrane showing potassium ion channels (Kir 7.1) and potassium ions (K+). The image depicts subretinal space, RPE cells, and the gene KCNJ13 associated with potassium ion channels.
Diagram illustrating congenital alacrima type 16 (LCA16). It shows a side view of a cell membrane with dysfunctional Kir 7.1 potassium ion channels marked with red crosses, and various potassium ions (K+) represented as pink circles outside and insid
Diagram illustrating how the eye perceives an apple, showing the retina with photo receptors and the pathway of light from the apple through the eye.
Diagram of the retina showing photoreceptors, retinal pigment epithelium (RPE), and the light spectrum, with labels for each component.
Illustration of molecular interactions with cells and DNA, showing decline over time, with logos of HubbleTX and LCA16.
An illustration showing a mouse receiving a subretinal injection of a treatment labeled 'HUB-101' for animal studies. The inset diagram depicts the process of the treatment targeting diseased retina cells in an LCA16 mouse model, with molecules passi
An illustration demonstrating a single subretinal injection of HUB-101, a gene therapy treatment, into the eye with a syringe. The eye's anatomy is visible, with the needle inserted into the eye, and a molecular structure representing HUB-101 is show
Diagram illustrating the potassium ion channel (LCA16) in the subretinal space. It shows RPE cells, potassium ions (K+), and the functional Kir 7.1 potassium ion channel with labels indicating the subretinal space, the channel, and a genetic element.